PROSTATE CANCER

 

WHERE TO FIND US

• The Christie NHS Foundation Trust
• MCRC building
• CRUK MI
• Salford Royal NHS Foundation Trust

The heart of our prostate cancer research is the FASTMAN Movember Centre of Excellence, which unites both hospital and research laboratory in two cities: Manchester and Belfast.

Within discovery science, we are exploring recurrence and metastasis. Our scientists are characterising the molecular pathways that regulate tumour-initiating/propagating cells, which are responsible of tumour recurrence, to develop novel therapeutics that tackle the residual disease. Others are working to better understand the mechanism of metastasis in prostate cancer, especially the targeted metastasis towards the bone, and the role of lipid metabolism. We also have an active interest in the characterisation of new diagnostic and prognostic biomarkers, harnessing expertise in biomedical spectroscopy at the Manchester Institute of Biotechnology.

Translational research is focused on genomics and radiobiology. We have developed hypoxia gene signatures to enable identification of those patients who would benefit from hypoxia-modifying agents prior to radiotherapy. Our researchers are also looking at the interplay between hypoxia and DNA repair mechanisms, and how they lead to genetic instability and prostate cancer aggression.

Our clinical researchers support biomarker-driven clinical trials of novel treatments for prostate cancer; similar approaches will be implemented for bladder and penile cancers. The aim is to further personalise medicine in this disease site using precise radiotherapy targeting, molecularly targeted drugs and immunotherapy. Within precision radiotherapy, we are optimising the use of new techniques (MR-linac, proton therapy, brachytherapy) and response imaging technology (oxygen-enhanced MRI) to marry the optimal physical and biological targeted therapies for individual patients. 

KEY PUBLICATIONS

The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.
Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua MLK, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, Salcedo A, Houlahan KE, Li CH, Huang V, Fraser M, van der Kwast T, Morris QD, Bristow RG, Boutros PC.
Cell. 2018 May 3;173(4):1003-1013.e15. doi: 10.1016/j.cell.2018.03.029. 

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.
Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.
EBioMedicine. 2018 Apr 23. pii: S2352-3964(18)30147-6. doi: 10.1016/j.ebiom.2018.04.019. 

Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.
Gong J, Omlin A, Pal SK, Hsu J, Tombal B, Sydes MR, Gillessen S.
Eur Urol. 2018 May 3. pii: S0302-2838(18)30330-0. doi: 10.1016/j.eururo.2018.04.024.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.
Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. 

Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, Lau M, Maddineni S, Brown M, Clarke N.
Eur Urol Focus. 2018 Apr 23. pii: S2405-4569(18)30096-8. doi: 10.1016/j.euf.2018.04.006.

WHO'S WHO

Medical Oncology

  • Silke Gillessen

Clinical Oncology

Urology